ITM-11 beats everolimus in Phase 3 GEP-NETs trial; ITM plans filing. Drug will compete with Novartis's Lutathera. Both use ...

Another obesity biotech emerged on Tuesday morning, this time taking a different approach to the GIP antagonism story than ...

In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and ...

For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering ...

Affini-T Therapeutics appears to have cut staff last week, according to LinkedIn posts from people who say they are or were ...

Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene ...

The state of Hawaii can proceed with a lawsuit against the three largest pharmacy benefit managers after it updated its ...

Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...

Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its ...

Investors typically celebrate IPOs as milestone moments — and potential exit opportunities — for their startups. In an ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...